Hikma launches caffeine citrate injection, commercialising the first of the Bedford products

London, 12 May 2015 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today announces it has launched CAFCIT® Injection (caffeine citrate injection, USP) 60mg/3mL (20mg/mL). CAFCIT® is indicated for the short-term treatment of apnea of prematurity in infants between 28 and 33 weeks gestational age.

Press Release Corporate 12 May 2015

Said Darwazah, Chairman and CEO of Hikma said, “This is our first launch from the Bedford portfolio acquired last year. We are making good progress in the transfer of the Bedford products to our manufacturing facilities and this launch demonstrates our strong R&D, regulatory and manufacturing capabilities."

According to IMS Health, sales of caffeine citrate injection in the US market were approximately $7.6 million for the 12 months ending March 2015.

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.